Fourth Covid dose decision delayed as booster effectiveness data remains incomplete

In mid-February 2022, the White House faced a decision it was not yet ready to make. New data from the Centers for Disease Control and Prevention showed that the protective power of COVID-19 booster shots was fading—dropping from 91 percent effectiveness against hospitalization in the first two months after a third dose to 78 percent after four to five months. The same pattern held for emergency room visits: protection fell from 87 percent to 66 percent over the same timeframe. The numbers came from a study of hospitalizations and urgent care visits across ten states among people who had received boosters from either Moderna or Pfizer. The question hanging over the administration was whether these findings meant Americans should now receive a fourth shot.

Dr. Peter Marks, who oversees vaccine regulation at the Food and Drug Administration, offered a cautious answer: not yet. "We simply don't have enough data to know that it's a good thing to do," he said. The CDC's own analysis came with significant limitations. Researchers had not broken down the data by age group, had not accounted for underlying medical conditions, and had not examined how immune deficiencies might affect the results. These gaps mattered. Without understanding how protection waned across different populations, health officials could not confidently recommend a fourth dose to the entire country.

Dr. Anthony Fauci, the White House's chief medical adviser, acknowledged the decline in booster effectiveness but framed it differently. Even at 78 percent, he argued, protection against severe illness remained robust. "Seventy-eight percent is good," he said, noting that people asking him whether they should get a fourth shot were asking the right question at the wrong time. The administration's vaccine strategy had been under constant revision since President Biden took office, and this decision would follow the same pattern: wait, watch, and reassess.

What would trigger a shift? Fauci pointed to two possibilities. First, if protection from the third dose continued to decline beyond the four-to-five-month mark, the case for a fourth shot would strengthen. Second, if new variants emerged with the ability to evade existing immunity, the calculus would change overnight. For now, neither condition had been met. The data suggested a plateau rather than a cliff—protection was waning, but it was not collapsing.

FDA officials were already thinking ahead to the fall. Dr. Marks suggested that if a fourth dose eventually became necessary, autumn might be the optimal time to administer it. By then, coronavirus transmission typically increased, and the flu season was beginning. Coordinating a fourth COVID shot with the annual influenza vaccination campaign could maximize uptake and efficiency. "Maybe the best thing is to think about our booster strategy in conjunction with the influenza vaccine next fall and get as many people as possible boosted then," Marks said. That strategy hinged on one condition: no major surprises from new variants between now and then. The administration was buying time, waiting for clearer evidence before committing to a fourth dose for the general population.